Virtual Library
Start Your Search
Isabel Curto
Author of
-
+
P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.15-24 - Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients (ID 13200)
16:45 - 18:00 | Author(s): Isabel Curto
- Abstract
Background
Lung cancer is the leading cause of death from cancer, of which 15% corresponds with small cell lung cancer (SCLC) subtype, directly related with tobacco. SCLC is the most aggressive subtype with an elevated percentage of metastatic patients at diagnosis and a poor prognosis.
a9ded1e5ce5d75814730bb4caaf49419 Method
A cohort of 221 patients diagnosed of SCLC were retrospectively analyzed in our center between 2008-2016.
Patient data was analyzed for baseline demographics and stage at diagnosis.
Progression free survival (PFS) and overall survival (OS) analysis were made comparing SCLC stage at diagnosis.
4c3880bb027f159e801041b1021e88e8 Result
The median age at diagnosis was 64 years and 74% were male, of whom 33% were older than 70 years. Only 0.5 % were never smokers and 16% had history of other malignancies, mostly related with tobacco. At diagnosis, 67% were metastatic and 88% symptomatic.
Complete baseline characteristics shown at Table 1.
PFS was 13.5 versus 6.83 months in located versus metastatic disease (p = 0.000) and median OS was 21.2 versus 8.5 months comparing located and metastatic stage (p = 0.000).
Kaplan-Meier curves shown at Image 1.
8eea62084ca7e541d918e823422bd82e ConclusionTable 1. Complete baseline characteristics. BASELINE CHARACTERISTICS ALL PATIENTS (n=221) SEX 164 (74%) male; 57 (26%) female AGE AT DIAGNOSIS 64 years (IQR 58-71); 65 years (IQR 59-73) male; 61 years (IQR 55-68) female. PATIENTS OLDER THAN 70 YEARS 72 (33%); 60 males and 12 females SMOKING HABIT Smoker --> 137 (61.9%)
Former smoker --> (> 365 days without smoking) à 81 (36.65%)
Never smoker --> 1 (0.45%)
Unknown --> 2 (0.9%)SMOKING PACK YEAR 58 pack/year; 60 pack/year male and 50 pack/year female AGE AT THE BEGINNING OF TOBACCO HABIT
16 years STAGE Stage I --> 10 (5%)
Stage II --> 8 (4%)
Stage III --> 53 (24%)
Stage IV --> 150 (67%)
ECOG 0-1--> 191 (86.4%)
2--> 23 (10.4%)
3--> 7 (3.2%)
CARDIOPULMONARY DISEASE COPD 23%
HBP 47%
DM 25%
DL 43%
Cardiopathy 19%HISTORY OF OTHER MALIGNANCIES 16%, most frequent: bladder cancer 7 (20.6%); head and neck cancer 6 (17.7%); lung cancer 4 (11.8%) FAMILIAR HISTORY OF LUNG CANCER 39% SYMPTOMS AT DIAGNOSIS Cough 42%; weight loss 30%; pain 28%; dyspnoea 27%; asthenia 21% TREATMENT 8.2% palliative treatment
91.8% active treatment (98.8% standard treatment with platinum-based chemotherapy and 1.2% clinical trial)PROGRESSION FREE SURVIVAL 13.5 (IQR 7.4-40.8) months in located and 6.8 (IQR 4.8-10.2) in metastatic disease compared with (p = 0.000)
OVERALL SURVIVAL 21.2 (IQR 10.8-39.6) months in located and 8.5 (IQR 3.9-15.5) in metastatic disease with (p = 0.000)
12 AND 24-MONTHS OVERALL SURVIVAL Located: 73% and 42% respectively
Metastatic: 33% and 15% respectively
SCLC is mostly diagnosed at metastatic stage, but even in located disease prognosis is poor, so investigation is needed to improve PFS and OS.
6f8b794f3246b0c1e1780bb4d4d5dc53